HARMONY Alliance participates in EBMT2024

17 April 2024 - 12:30 - 13:45 hrs - in room Boisdale.

Joint EBMT-HARMONY session program

EBMT’s view on sharing data and data-driven research to offer new opportunities for bone marrow transplant professionals: Anna Sureda, EBMT President (chair)

Data-innovation in MDS: Converting data into insights: Valeria Santini, University of Florence, HARMONY Alliance, EHA SWG on Myelodysplastic Syndromes (MDS) Executive Board

Data-innovation in MDS: Transplant vs. non-transplant strategies in MDS: a joint EBMT-HARMONY study: Carmelo Gurnari, University of Rome Tor Vergata, Vice-chair MDS subcommittee EBMT-CMWP (Chronic Malignancies Working Party)

Data-innovation in AML - The HARMONY AML risk of relapse tool to guide alloHSCT decision-making: Lars Bullinger, Charité – Universitätsmedizin Berlin, HARMONY Alliance, EHA SWG for Acute Myeloid Leukemia (AML)

The program includes a round table discussion with the session participants about sharing data and joint research opportunities in MDS and AML. The round table panel will consist of:

Donal McLornan, Chair EBMT-CMWP (Chronic Malignancies Working Party)

Fabio Ciceri, Chair EBMT-ALWP (Acute Leukemia Working Party)

Valeria Santini, University of Florence, HARMONY Alliance, EHA SWG on Myelodysplastic Syndromes (MDS) Executive Board

Carmelo Gurnari, University of Rome Tor Vergata, Vice-chair MDS subcommittee EBMT-CMWP

Lars Bullinger, Charité – Universitätsmedizin Berlin, HARMONY Alliance, EHA SWG for Acute Myeloid Leukemia (AML)

Anna Sureda, EBMT President (session chair)

The HARMONY Alliance would like to thank EBMT for this opportunity.

Would you like to connect with us at EBMT2024?

Mail us to schedule an appointment: communications@harmony-alliance.eu

Receive the latest news. Click here to subscribe!

Public-private partnership for Big Data in Hematology

HARMONY and HARMONY PLUS are funded through the Innovative Medicines Initiative (IMI), Europe's largest public-private initiative aiming to speed up the development of better and safer medicines for patients. Funding is received from the IMI 2 Joint Undertaking and is listed under grant agreement for HARMONY No. 116026 and grant agreement for HARMONY PLUS No. 945406. This Joint Undertaking receives support from the European Union’s Horizon 2020 Research and Innovation Programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA).